bioAffinity expands CyPath Lung access for U.S. veterans
TipRanks (Wed, 30-Sep 9:01 AM ET)
Business Wire (Wed, 30-Sep 8:00 AM ET)
BIAF Highlights 2,000-Patient VA/Military FlowPath Lung Study as CyPath Lung Heads to NAVREF 2026
Market Chameleon (Tue, 22-Sep 7:41 AM ET)
Business Wire (Tue, 22-Sep 8:00 AM ET)
Market Chameleon (Fri, 18-Sep 5:53 AM ET)
Four High-Impact Small Caps Enter the Spotlight
Globe Newswire (Thu, 17-Sep 11:37 AM ET)
Business Wire (Thu, 17-Sep 8:00 AM ET)
Four Biotech Stories Heating Up Right Now
Globe Newswire (Wed, 9-Sep 11:55 AM ET)
bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements
Business Wire (Wed, 9-Sep 8:00 AM ET)
Business Wire (Thu, 3-Sep 4:30 PM ET)
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.
Bioaffinity Technologies trades on the NASDAQ stock market under the symbol BIAF.
As of October 2, 2026, BIAF stock price declined to $6.05 with 128,133 million shares trading.
BIAF has a beta of -3.15, meaning it tends to be less sensitive to market movements. BIAF has a correlation of 0.04 to the broad based SPY ETF.
BIAF has a market cap of $3.64 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, BIAF traded as high as $1,629.00 and as low as $4.56.
The top ETF exchange traded funds that BIAF belongs to (by Net Assets): VXF.
BIAF has underperformed the market in the last year with a price return of -85.5% while the SPY ETF gained +16.1%. BIAF has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -51.4% and -35.8%, respectively, while the SPY returned +3.6% and +1.0%, respectively.
BIAF support price is $5.10 and resistance is $7.19 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BIAF shares will trade within this expected range on the day.
